EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction

Brian Drachman, Thibaud Damy, Mazen Hanna, Ronnie Wang, Franca S Angeli, Pablo Garcia-Pavia

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3330 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Brian Drachman und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Pennsylvania Health System, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Stroke Volume, Benzoxazoles, Cardiomyopathies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) present with diverse left ventricular ejection fraction (LVEF). This study assessed tafamidis efficacy by baseline LVEF in the phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and its long-term extension (LTE) study. Methods and results Patients were randomized to 30 months of tafamidis or placebo treatment in ATTR-ACT. On completion, patients could join an LTE study to receive tafamidis. All-cause mortality (death, heart transplant, or cardiac mechanical assist device implantation) from baseline to the end of follow-up was assessed in patients continuously treated with tafamidis (80 mg meglumine or 61 mg free acid) or delayed tafamidis treatment (placebo in ATTR-ACT; tafamidis in the LTE study) according to baseline LVEF (<50% or ≥50%). Supportive outcomes were evaluated over a shorter follow-up. Patients with baseline LVEF <50% (n = 177: 88 tafamidis- and 89 placebo-treated) had signs of more severe heart failure, a higher proportion were Black, and had variant ATTR-CM than those with LVEF ≥50% (n = 171: 85 tafamidis- and 86 placebo-treated). At the end of follow-up (median 60–64 months), all-cause mortality was numerically higher in patients with baseline LVEF <50%; however, consistent with supportive findings, continuous tafamidis treatment was associated with a 47% reduction in mortality risk compared with delayed tafamidis treatment in patients with LVEF <50% and ≥50% (hazard ratio 0.53 [95% confidence interval 0.367–0.758]; p < 0.001, and 0.53 [0.344–0.818]; p < 0.01, respectively).

Conclusions

Early initiation of tafamidis is associated with reduced mortality in patients with ATTR-CM, irrespective of initial LVEF value. Clinical Trial Registration: ClinicalTrials.gov NCT01994889, NCT02791230.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialStroke VolumeBenzoxazolesCardiomyopathiesHumansMaleFemaleMiddle AgedAgedTreatment OutcomeVentricular Function, LeftDouble-Blind MethodFollow-Up StudiesTime Factors

Stichwörter der Autor:innen

6‐min walk testHeart failureMildly reduced ejection fractionPreserved ejection fractionQuality of lifeReduced ejection fraction

Substanzen

tafamidisBenzoxazoles

Autor:innen und Institutionen

  • University of Pennsylvania Health System, Philadelphia, PA, USA.
  • Referral Center for Cardiac Amyloidosis, CHU Henri Mondor, Créteil, France.
  • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Pfizer Inc., Groton, CT, USA.
  • Pfizer Inc., New York, NY, USA.
  • Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, Madrid, Spain.

Förderung

  • Pfizer

Zitieren

APA

Drachman, B., Damy, T., Hanna, M., Wang, R., Angeli, F. S., & Garcia-Pavia, P. (2024). Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3330

Vancouver

Drachman B, Damy T, Hanna M, Wang R, Angeli FS, Garcia-Pavia P. Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3330

BibTeX
@article{Drachman2024,
  author = {Drachman, Brian and Damy, Thibaud and Hanna, Mazen and Wang, Ronnie and Angeli, Franca S and Garcia-Pavia, Pablo},
  title = {Long-Term Tafamidis Efficacy in Patients with Transthyretin Amyloid Cardiomyopathy by Baseline Left Ventricular Ejection Fraction},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3330}
}
Kostenlos starten →